One Week’s Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and alpha- and beta-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes - Degn, K B; Juhl, C B; Sturis, J (Diabetes, 2004)
et al.